Clinical Trial Update: Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial updates the use of blinatumomab in Japanese patients with relapsed/refractory B-precursor ALL; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-precursor Acute Lymphoblastic Leukemia

Drugs mentioned

• Blinatumomab (blinatumomab)

Snippet

Sponsor: Amgen | Conditions: Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-01-10